Extracellular matrix remodelling in myocardial hypertrophy and failure: focus on osteopontin

High Blood Pressure and Cardiovascular Prevention

Volumn 16, Issue 4, 2009, Pages 195-199

  Francia, Pietro ^a   Uccellini, Arianna ^a   Frattari, Alessandra ^a   Modestino, Anna ^a   Ricotta, Agnese ^a   Balla, Cristina ^a   Scialla, Ludovica ^a   Volpe, Massimo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Cardiac remodelling; Extracellular matrix; Heart failure; Osteopontin

Indexed keywords

ANGIOTENSIN II; GLYCOPROTEIN; MESSENGER RNA; OSTEOPONTIN;

CONGESTIVE CARDIOMYOPATHY; EXTRACELLULAR MATRIX; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; HYPOXIA; IMMUNOREACTIVITY; INTERSTITIUM; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; RENOVASCULAR HYPERTENSION; REVIEW;

EID: 76249086249     PISSN: 11209879     EISSN: 11791985     Source Type: Journal    
DOI: 10.2165/11530450-000000000-00000     Document Type: Review

References (49)

1. Oldberg A, Franzen A, Heinegard D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci U S A 1986; 83: 8819-8823
2. Hiroshi Okamoto. Osteopontin and cardiovascular system.Mol Cell Biochem 2007; 300: 1-7
3. Peter, Zahradka. Novel role for osteopontin in cardiac fibrosis. Circ Res 2008; 102: 270-272
4. Ashizawa N, Graf K, Do YS, et al. Osteopontin is produced by rat cardiac fibroblasts and mediates AII-induced DNA synthesis and collagen gel contraction. J Clin Invest 1996; 98: 2218-2227
5. Aplin AE, Howe A, Alahari SK, et al. Signal transduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, immunoglobulin- cell adhesion molecules, and selectins. Pharmacol Rev 1998; 50: 197-263
6. Graf K, Do YS, Ashizawa N, et al. Myocardial osteopontin expression is associated with left ventricular hypertrophy. Circulation 1997; 96: 3063-3071
7. Chon JN, Ferrari R, Sharpe N. Cardiac remodelling: concepts and clinical implications - a consensus paper from an international forum on cardiac remodeling. On behalf on an international forum on cardiac remodeling. J Am Coll Cardiol 2000; 35: 569-582
8. Pfeffer MA, Pfeffer JM, Fishbein MC, et al. Myocardial infarct size and ventricular function in rats. Circ Res 1979; 44: 503-512
9. Hinz B, Phan SH, Thannickal VJ, et al. The myofibroblast: one function, multiple origins. Am J Pathol 2007; 170: 1807-1816
10. Schnee JM, Hsueh WA. Angiotensin II, adhesion and cardiac fibrosis. Cardiovasc Res 2000; 46: 264-268
11. Yamazaki T, Komuro I, Yazaki Y. Role of the renin-angiotensin system in cardiac hypertrophy. Am J Cardiol 1999; 83: H53-7
12. Ohta K, Kim S,WanibuchiH, et al. Contribution of the local renin-angiotensin system to cardiac hypertrophy, phenotypic modulation, and remodeling in TGR(mRen2)27 transgenic rats. Circulation 1996; 94: 785-791
13. Pfeffer JM, Fischer TA, Pfeffer MA. Angiotensin converting enzyme inhibition and ventricular remodeling after myocardial infarction. Annu Rev Physiol 1995; 57: 805-826
14. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849-1865
15. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARMoverall programme. Lancet 2003; 362: 759-766 (Pubitemid 37093915)
16. Rogers WJ, Johnstone DE, Yusuf S, et al. Quality of life among 5 025 patients with left ventricular dysfunction randomized between placebo and enalapril: the Studies of Left Ventricular Dysfunction. The SOLVD Investigators. J Am Coll Cardiol 1994 Feb; 23 (2): 393-400
17. Rosenkranz S. TGF-b1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 2004; 63: 423-432
18. Villarreal FJ, Lee AA, Dillmann WH, et al. Adenovirus-mediated overexpression of human transforming growth factor-beta 1 in rat cardiac fibrobasts, myocytes and smooth muscle cells. J Mol Cell Cardiol 1996; 28: 735-742
19. Heimer R, Bashey RI, Kyle J, et al. TGF-beta modulates the syntesis of proteoglycans by myocardial fibroblasts in culture. J Mol Cell Cardiol 1995; 27: 2191-2198
20. Eghbali M, Tomek R, Sukhatme VP, et al. Differential effects of transforming growth factor-beta 1 and phorbol myristate acetate on cardiac fibroblasts: regulation of fibrillar collagen mRNAs and expression of early transcription factors. Circ Res 1991; 69: 483-490
21. Desmouliere A, Geinoz A, Gabbiani F, et al. Transforming growth factorbeta 1 induces alfa-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Biol Chem 1993; 122: 103-111
22. Murry CE, Giachelli CM, Schwartz SM, et al. Macrophages express osteopontin during repair of myocardial necrosis. Am J Pathol 1994; 145: 1450-1462
23. Williams EB, Halpert I, Wickline S, et al. Osteopontin expression is increased in the heritable cardiomyopathy of Syrian hamsters. Circulation 1995; 92 (4): 705-709
24. Trueblood NA, Xie Z,Communal C, et al. Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin. Circ Res 2001; 88: 1080-1087
25. ChambersAF,HotaC, PrinceCW.Adhesion ofmetastatic, ras-transformedNIH 3T3 cells to osteopontin, fibronectin and laminin. Cancer Res 1993; 53: 701-706
26. Miyauchi A, Alvarez J, Greenfield EM, et al. Recognition of osteopontin and related peptides by an avf3 integrin stimulates immediate cell signals in osteoclasts. J Biol Chem 1991; 260: 20369-20374
27. Tamura A, Shingai M, AsoN, et al. Osteopontin is released from the heart into the coronary circulation in patients with a previous anterior wall myocardial infarction. Circ J 2003; 67: 742-744
28. Suezawa C, Kusachi S, Murakami T, et al. Time dependent changes in plasma osteopontin levels in patients with anterior-wall acute myocardial infarction after successful reperfusion: correlation with left-ventricular volume and function. J Lab Clin Med 2005; 145: 33-40
29. Xie Z, Singh M, Singh K. Osteopontin modulates myocardial hypertrophy response to chronic pressure overload in mice. Hypertension 2004; 44: 826-831
30. Matsui Y, Jia N, Okamoto H, et al. Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy. Hypertension 2004; 43: 1164-1165
31. Lenga Y, Koh A, Perera AS, et al. Osteopontin expression is required for myofibroblast differentiation. Circulation 2008; 102: 319-327
32. Wenzel S, Taimor G, Piper HM, et al. Redox-sensitive intermediates mediate angiotensin II-induced p38 MAP kinase activation, AP-1 binding activity, and TGF-h expression in adult ventricular cardiomyocytes. FASEB J 2001; 15: 2291-2293
33. Kim S, Ohta K, Hamaguchi A, et al. Angiotensin II type I receptor antagonist inhibits the gene expression of TGF-h1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats. J Pharmacol Exp Ther 1995; 273: 509-515
34. Crawford D, Chobanian A, Brecher P. Angiotensin II induces fibronectin expression associated with cardiac fibrosis in the rat. Circ Res 1994; 74: 727-739
35. Hao J, Wang B, Jones SC, et al. Interaction between angiotensin II and Smad proteins in fibroblasts in failing heart and in vitro. Am J Physiol Heart Circ Physiol 2000; 279: H3020-30
36. Wang B, Hao J, Jones SC, et al. Decreased Smad 7 expression contributes to cardiac fibrosis in the infarcted rat heart. Am J Physiol Heart Circ Physiol 2002; 282: H1685-96
37. Dixon IM, Hao J, Reid NL, et al. Effect of chronic AT(1) receptor blockade on cardiac Smad overexpression in hereditary cardiomyopathic hamsters. Cardiovasc Res 2000; 46: 286-297
38. Zhang D, Gaussin V, Taffet GE, et al. TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. Nat Med 2000; 6: 556-563
39. Rosenkranz S, Flesch M, Amann K, et al. Alterations of h-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-h1. Am J Physiol Heart Circ Physiol 2002; H1253-62
40. Rosenkranz S, Amann K, Caglayan E, et al. h-adrenoceptor blockade prevents cardiac hypertrophy and failure in TGF-h transgenic mice [abstract]. Eur J Heart 2003; 24 Suppl.: 665
41. Schluter K-D, Zhou XJ, Piper HM. Induction of hypertrophic responsiveness to isoproterenol by TGF-h in adult rat cardiomyocytes. Am J Physiol 1995; 269: C1311-6
42. Schluter KD, Frischkopf K, Flesch M, et al. Central role for ornithine decarboxylase in h-adrenoceptor mediated hypertrophy. Cardiovasc Res 2000; 45: 410-417
43. Singh M, Foster CR, Dalal S, et al. Osteopontin: role in extracellular matrix deposition and myocardial remodeling post-MI. J Mol Cell Cardiol. Epub 2009 Jun 30
44. Stawowy P, Blaschke F, Pfautsch P, et al. Increased myocardial expression of osteopontin in patients with advanced heart failure. Eur J Heart Fail 2002; 4: 139-146
45. Kramer F, Sandner P, Klein M, et al. Plasma concentrations of matrix metalloproteinase-2, tissue inhibitor of metalloproteinase-1 and osteopontin reflect severity of heart failure in DOCA-salt hypertensive rat. Biomarkers 2008 May; 13 (3): 270-281
46. Soejima H, Irie A, Fukunaga T, et al. Osteopontin expression of circulating T cells and plasma osteopontin levels are increased in relation to severity of heart failure. Circulation 2007; 71: 1879-1884
47. Milting H, Ellinghaus P, Seewald M, et al. Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Heart Lung Transplant 2008 Jun; 27 (6): 589-596
48. Rosenberg M, Zugck C, Nelles M, et al. Osteopontin: a new prognostic biomarker in patients with chronic heart failure. Circ Heart Fail 2008; 1: 43-49
49. Arnlov J, Evans JC, Benjamin EJ, et al. Clinical and echocardiographic correlates of plasma osteopontin in the community: the Framingham Heart Study. Heart 2006; 92 (10): 1514-1515